Enhancing postmarketing surveillance: continuing challenges.
作者信息
French Dustin D, Margo Curtis E, Campbell Robert R
机构信息
Center for Healthcare Studies, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Veterans Affairs Health Services Research and Development, Chicago, IL, USA.
出版信息
Br J Clin Pharmacol. 2015 Oct;80(4):615-7. doi: 10.1111/bcp.12658. Epub 2015 Jun 1.
Abstract
摘要
相似文献
1
Enhancing postmarketing surveillance: continuing challenges.加强上市后监测：持续面临的挑战。
Br J Clin Pharmacol. 2015 Oct;80(4):615-7. doi: 10.1111/bcp.12658. Epub 2015 Jun 1.
2
Postmarketing surveillance and reporting of adverse drug events.药品上市后监测及药品不良反应报告。
S D J Med. 2004 Jan;57(1):13-4.
3
Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.上市后监测中的药物基因组学分析：前景与挑战。
Pharmacogenomics. 2003 Sep;4(5):647-55. doi: 10.1517/phgs.4.5.647.23793.
4
Postmarketing surveillance-one of the key issues in drug development.上市后监测——药物研发中的关键问题之一。
Ther Hung. 1992;40(4):147-53.
5
Reporting of adverse drug events: a key to postmarketing drug safety.药品不良事件报告：上市后药品安全的关键
Am Fam Physician. 1992 Sep;46(3):873-4.
6
Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.眼部药物不良反应上市后监测中的科学挑战。
Am J Ophthalmol. 2007 Jan;143(1):145-149. doi: 10.1016/j.ajo.2006.10.005. Epub 2006 Nov 13.
7
The demise of postmarketing surveillance.上市后监测的消亡。
Adverse Drug React Toxicol Rev. 1995 Spring;14(1):7-9.
8
Postmarketing surveillance: beyond MEDWatch.上市后监测：超越MEDWatch
JAMA. 1993 Nov 10;270(18):2180.
9
Xyrem (sodium oxybate) postmarketing adverse event reporting system.羟丁酸钠上市后不良事件报告系统。
Sleep Med. 2010 Jun;11(6):595; author reply 595-6. doi: 10.1016/j.sleep.2010.02.003. Epub 2010 Apr 1.
10
Postmarketing surveillance--lack of vigilance, lack of trust.上市后监测——警惕性不足，信任缺失。
JAMA. 2004 Dec 1;292(21):2647-50. doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22.
引用本文的文献
1
Applying Machine Learning Techniques to Predict Drug-Related Side Effect: A Policy Brief.应用机器学习技术预测药物相关副作用：政策简报。
Inquiry. 2025 Jan-Dec;62:469580251335805. doi: 10.1177/00469580251335805. Epub 2025 Jun 13.
2
Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada.上市后监测：关于英国和加拿大背景下有效运作的关键方面及措施的综述
Ther Adv Drug Saf. 2019 Jul 26;10:2042098619865413. doi: 10.1177/2042098619865413. eCollection 2019.
本文引用的文献
1
Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.2001年至2010年间欧洲药品管理局批准的新型药物的监管审查时间和上市后安全事件：一项横断面研究。
Br J Clin Pharmacol. 2015 Oct;80(4):716-26. doi: 10.1111/bcp.12643. Epub 2015 May 28.
2
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.急性非动脉炎性前部缺血性视神经病变与5型磷酸二酯酶抑制剂的暴露
J Sex Med. 2015 Jan;12(1):139-51. doi: 10.1111/jsm.12726. Epub 2014 Oct 31.
3
Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.磷酸二酯酶-5抑制剂与非动脉炎性前部缺血性视神经病变之间的关联。
J Neuroophthalmol. 2015 Mar;35(1):12-5. doi: 10.1097/WNO.0000000000000186.
4
Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.美国食品药品监督管理局（FDA）加快药品审批的时代，黑框警告和药品退市情况也有所增加。
Health Aff (Millwood). 2014 Aug;33(8):1453-9. doi: 10.1377/hlthaff.2014.0122.
5
Rooting out institutional corruption to manage inappropriate off-label drug use.铲除体制性腐败以治理不当的药品标签外使用。
J Law Med Ethics. 2013 Fall;41(3):654-64. doi: 10.1111/jlme.12075.
6
Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.对同时开具磷酸二酯酶-5抑制剂与有机硝酸盐或α受体阻滞剂的男性退伍军人缺血性视神经病变进行上市后监测。
Drug Saf. 2008;31(3):241-7. doi: 10.2165/00002018-200831030-00005.
7
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.服用磷酸二酯酶-5抑制剂的男性退伍军人中的缺血性视神经病变
Am J Ophthalmol. 2007 Mar;143(3):538-9. doi: 10.1016/j.ajo.2006.10.006. Epub 2006 Nov 13.
8
Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.使用西地那非（伟哥）后不久发生的非动脉炎性缺血性视神经病变：7例新病例报告
J Neuroophthalmol. 2005 Mar;25(1):9-13. doi: 10.1097/00041327-200503000-00003.
Zotero 插件